Trade Halozyme Therapeutics
Halozyme Therapeutics is a U.S. biotechnology company that develops new oncology treatments designed to target the microtumor environment and licenses new technology to deliver medicines through corporate partnerships. company was founded in 1998 and went to 2004. Halozyme is headquartered in San Diego, California. Halozyme's work focuses primarily on proprietary and patented human hyaluronidaze enzyme, rHuPH20. The company's development pipeline is focused on clinical and preclinical oncology products, including its own investigative drug, PEGPH20, a version of rHuPH20, which targets high tumors in hyaluron (HA). The company is in various stages of clinical trials with PEGPH20 across multiple types of solid tumors, including pancreatic cancer, non-small cell lung cancer (NSCLC), and stomach cancer, to test the safety and effectiveness of the drug. Halozyme is one FDA-approved product (Hylenex re-compenant, human injection hyaluronidase). The company also licenses Enhanze pharmaceutical delivery technology to other biopharmaceutical companies, including Roche, Baxalta, Pfizer, Jansen, AbbVie, and Lilly.